



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

Date: 31.07.2017

1. The Secretary,
Bombay Stock Exchange Ltd
Phiroze Jeejeebhoy Towers
Dalal Street, MUMBAI 400 001
2. The Secretary,
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra (E), MUMBAI 400 051
3. The Secretary,
Ahmedabad Stock Exchange Ltd
Kamdheni Complex
Opp Sahajanand College
Panjarpole, AHMEDABAD 380 015

Company Code: 537291

Sub:Submission of information under regulation 33 (3) (a) of the SEBI (LODR) Regulations , 2015.

Dear sir ,

Please find enclosed herewith Quarterly unaudited Results for the quarter ended 30th June 2017.

The above information is being provided to you under Regulation 33 (3) (a) of The SEBI (LODR) Regulations, 2015.

This is for your information and record purpose.

Thanking You.

Yours Faithfully,

For Nath Bio Genes (India) Limited

Authorized Signatory

■ Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com

■ 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

NATH
GROUP



Gautam N Associates

Chartered Accountants

30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

LIMITED REVIEW REPORT

To
The Board of Directors of
NATH BIO-GENES (INDIA) LIMITED

1. We have reviewed the accompanying statement of unaudited financial results for the quarter ended 30th June 2017 (the Statement) of NATH BIO-GENES (INDIA) LIMITED (the Company) except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoters Group Shareholding, which have been traced from the disclosure made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to enquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard -25 "Interim Financial Reporting", specified under the Companies Act, 1956 (which are deemed to be applicable as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation -33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material mis-statement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W


Gautam Nandawat
Partner
M No: 032742



Place: Aurangabad
Date: 31.07.2017



Nath Bio-Genes (I) Ltd.

(CIN L6110MH1993PLC672642)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 3 MONTHS ENDED 30/06/2017

Rs. in Lacs						
	3 Months ended	Preceding 3	Corresponding 3	Year to date	Year to date	Previous Year
	30/06/2017	Months ended	Months ended in	figures for current	figures for the	ended
	Unaudited	31/03/2017	the previous year	period ended	previous period	ended
	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
1 Income From Operations						
(a) Net Sales / Income from operations	10149.65	5076.98	8432.99	10149.65	8432.99	16972.56
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income from Operations	10149.65	5076.98	8432.99	10149.65	8432.99	16972.56
2 Expenses						
a) Cost of Material Consumed	1569.88	1625.59	1959.91	1569.88	1959.91	5845.98
b) Purchase of Stock-in-Trade	18.43	46.54	21.54	18.43	21.54	196.52
c) Changes in Inventory	3761.44	448.68	1764.61	3761.44	1764.61	1040.42
d) Employee benefit expense	383.65	366.86	443.78	383.65	443.78	1373.61
e) Depreciation & Amortisation	25.00	39.73	100.00	25.00	100.00	303.04
f) Selling & Distribution Expenses	1758.19	1363.45	2063.03	1758.19	2063.03	3903.67
g) Other Expenditure	321.31	1149.02	208.32	321.31	208.32	1727.25
Total Expenses	7837.90	5039.86	6561.19	7837.90	6561.19	14390.48
3 Profit / (Loss) from Operations before Other Income, Finance Cost & Exceptional Items (1-2)	2311.75	37.12	1871.80	2311.75	1871.80	2582.08
4 Other Income	5.35	29.87	11.98	5.35	11.98	65.91
5 Profit / (Loss) from Ordinary activities before Finance Cost & Exceptional Items (3-4)	2317.10	66.99	1883.77	2317.10	1883.77	2647.99
6 Finance Costs	285.40	291.37	234.28	285.40	234.28	965.71
7 Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)	2031.70	(224.38)	1649.49	2031.70	1649.49	1682.28
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit / (Loss) from ordinary activities before Tax (7-8)	2031.70	(224.38)	1649.49	2031.70	1649.49	1682.28
10 Tax expense	28.05	(12.90)	0.00	28.05	0.00	47.10
11 Net Profit / (Loss) from ordinary activities after Tax (9-10)	2003.65	(211.48)	1649.49	2003.65	1649.49	1635.18
12 Extraordinary Items	(13.86)	6.86	0.00	(13.86)	0.00	6.94
13 12)	2017.51	(218.33)	1649.49	2017.51	1649.49	1628.25
14 Share of Profit/(Loss) of Associates	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16 Net Profit/(Loss) after taxes, minority Interest and share of profit/(loss) of associates (13-14-15)	2017.51	(218.33)	1649.49	2017.51	1649.49	1628.25
17 Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1600.40	1600.40	1600.40	1600.40	1600.40	1600.40
18 Reserves (excluding Revaluation Reserves) as per balance sheet of	14175.75	12158.24	12179.49	14175.75	12179.49	12158.24
19 (i) Earning per share (before extra ordinary items) (not annualised)						
(a) Basic	12.52	(1.32)	10.31	12.52	10.31	10.22
(b) Diluted	12.52	(1.32)	10.31	12.52	10.31	10.22
19 (ii) Earning per share (after extra ordinary items) (not annualised)						
(a) Basic	12.61	(1.36)	10.31	12.61	10.31	10.17
(b) Diluted	12.61	(1.36)	10.31	12.61	10.31	10.17

NOTES:

- (1) Above financial results are taken on record by the Board of Directors in their meeting held on 31st July 2017.
- (2) The company is constantly improving its Product Mix for better profits and launching new research products in various crops.
- (3) The company has made adequate provisions for sales return and schemes for the sales made in this quarter.
- (4) The company is dealing in one major product segment, i.e. seeds for cultivation.
- (5) The Company has commenced accounting as per IAS from 1 Apr 2017.
- (6) Investor complaints - Opening Balance - 0, Received and Solved - 1, Closing Balance - 0

FOR NATH BIO-GENES (INDIA) LTD

Place : Aurangabad

Date : 31st July 2017

Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601

FOR GAUTAM N ASSOCIATES NATH
Regd. Office: Nath House, (1st Floor), Aurangabad - 431005 (MS)
www.nathbiogenes.com

CHARTERED ACCOUNTANTS

GAUTAM NANDAWAT
(Partner)



Nath Bio-Genes (India) Limited
Standalone Statement of Assets and Liabilities

Rs. In Lacs

Particulars	As at quarter end 30.06.2017	As at previous year end 31.03.2017
	(Unaudited)	(Audited)
A EQUITIES AND LIABILITIES		
1. Shareholders' Fund		
(a) Share capital	1600.40	1600.40
(b) Reserves and Surplus	14175.75	12158.24
(c) Money received against share warrants	0.00	0.00
Sub-total - Shareholders' Fund	15776.15	13758.64
2. Share application money pending for allotment	0.00	0.00
3. Minotiries Interest	0.00	0.00
4. Non-current liabilities		
a) Long Term Borrowings	1896.06	2006.71
b) Deferred Tax Liabilities	0.00	0.00
c) Other Long Term Liabilities	0.00	0.00
d) Long Term Provisions	210.65	200.65
Sub-total - Non-current liabilities	2106.71	2207.36
5. Current Liabilities		
a) Short Term Borrowings	4603.78	4860.88
b) Trade Payables	4732.16	4435.28
c) Other Current Liabilities	1415.28	3418.67
d) Short Term Provisions	282.64	254.59
Sub-total - Current liabilities	11033.85	12969.42
TOTAL - EQUITY AND LIABILITIES	28916.71	28935.42
B ASSETS		
(1) Non Current Assets		
a) Fixed Assets	4129.99	4156.59
b) Non Current Investments	499.69	499.68
c) Deferred Tax Assets (Net)	85.41	85.41
d) Long Term Loans and Advances	0.00	0.00
e) Other Non Current Assets	0.00	0.00
Sub-total - Non Current Assets	4715.08	4741.68
(2) Current Assets		
a) Current Investments	0.00	0.00
b) Inventories	9119.86	13015.09
c) Trade Receivables	7574.49	5182.46
d) Cash and Cash Equivalents	781.28	584.70
e) Short Term Loans and Advances	6623.12	5308.44
f) Other Current Assets	102.88	103.06
Sub-total - Current Assets	24201.63	24193.75
TOTAL ASSETS	28916.72	28935.42
	0.00	0.00

FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

Gautam N. Associates
GAUTAM NANDAWAT
(Partner)



FOR NATH BIO-GENES (INDIA) LTD

Satish Kagiwal
Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601

Place : Aurangabad
Date : 31st Jul 2017